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http://ccforum.com/content/17/5/R241RESEARCH Open AccessStress-dose hydrocortisone reduces critical
illness-related corticosteroid insufficiency associated
with severe traumatic brain injury in rats
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Introduction: The spectrum of critical illness-related corticosteroid insufficiency (CIRCI) in severe traumatic brain
injury (TBI) is not fully defined and no effective treatments for TBI-induced CIRCI are available to date. Despite
growing interest in the use of stress-dose hydrocortisone as a potential therapy for CIRCI, there remains a paucity of
data regarding its benefits following severe TBI. This study was designed to investigate the effects of stress-dose
hydrocortisone on CIRCI development and neurological outcomes in a rat model of severe traumatic brain injury.
Methods: Rats were subjected to lateral fluid percussion injury of 3.2-3.5 atmosphere. These rats were then treated
with either a stress-dose hydrocortisone (HC, 3 mg/kg/d for 5 days, 1.5 mg/kg on day 6, and 0.75 mg on day 7), a
low-dose methylprednisolone (MP, 1 mg/kg/d for 5 days, 0.5 mg/kg on day 6, and 0.25 mg on day 7) or control
saline solution intraperitoneally daily for 7 days after injury.
Results: We investigated the effects of stress-dose HC on the mortality, CIRCI occurrence, and neurological deficits
using an electrical stimulation test to assess corticosteroid response and modified neurological severity score
(mNSS). We also studied pathological changes in the hypothalamus, especially in the paraventricular nuclei (PVN),
after stress-dose HC or a low dose of MP was administered, including apoptosis detected by a TUNEL assay,
blood–brain barrier (BBB) permeability assessed by brain water content and Evans Blue extravasation into the
cerebral parenchyma, and BBB integrity evaluated by CD31 and claudin-5 expression. We made the following
observations. First, 70% injured rats developed CIRCI, with a peak incidence on post-injury day 7. The TBI-associated
CIRCI was closely correlated with an increased mortality and delayed neurological recovery. Second, post-injury
administration of stress-dose HC, but not MP or saline increased corticosteroid response, prevented CIRCI, reduced
mortality, and improved neurological function during the first 14 days post injury dosing. Thirdly, these beneficial
effects were closely related to improved vascular function by the preservation of tight junctions in surviving
endothelial cells, and reduced neural apoptosis in the PVN of hypothalamus.
Conclusions: Our findings indicate that post-injury administration of stress-dose HC, but not MP reduces CIRCI and
improves neurological recovery. These improvements are associated with reducing the damage to the tight
junction of vascular endothelial cells and blocking neuronal apoptosis in the PVN of the hypothalamus.* Correspondence: xinchentianjin@me.com; jianningzhang@hotmail.com
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Traumatic brain injury (TBI) remains a leading cause of
death and disability among adolescent males and young
adults in China, with an estimated annual cost of $20
billion for medical expenses. Approximately 1 million TBI
cases are reported each year in emergency rooms through-
out China, resulting in 100,000 deaths annually [1].
Critical illness-related corticosteroid insufficiency (CIRCI),
defined by the American College of Critical Care Medicine,
is used to describe dysfunctions of the hypothalamic-
pituitary-adrenal (HPA) axis that occurs during critical
illness [2]. It is characterized by an exaggerated and
protracted pro-inflammatory response and corticoster-
oid resistance, leading to an inadequate corticosteroid
response to severe stress [3]. The incidence of CIRCI
varies considerably (up to 77%) in patients with sepsis,
shock, acute respiratory distress syndrome (ARDS), and
severe pancreatitis [4-8]. Results from recent clinical trials
demonstrate that CIRCI is found in 50 to 70% of trauma
patients, with approximately 34% mortality despite therapy
[9]. However, the incidence of CIRCI in severe TBI has not
been fully defined [10].
The pathogenesis of CIRCI in the acute phase of TBI
has characteristic features that distinctively differ from
those found in other severe illness [11,12]. We have pre-
viously used electrical stimulation tests, which mimic
acute stress that activates the HPA axis in the sub-acute
phase of TBI, to assess the adrenal insufficiency in a rat
model of TBI. Pathological changes in the model rats are
similar in pathophysiology to CIRCI in patients as de-
fined by the American College of Critical Care Medicine
[13]. Our previous study in rats suggests that CIRCI
could develop during the acute phase of TBI and is
closely associated with increased mortality [13]. The apop-
tosis of cells in the adenohypophysis and in the paraven-
tricular nucleus (PVN) of the hypothalamus might be the
pathological characteristics of TBI-associated CIRCI. Add-
itional damage to the HPA axis could further aggravate
acute CIRCI, leading to a high fatality [13]. Interventions
targeting CIRCI have been implemented in such critical
illness [14] as septic shock [15], community-acquired
pneumonia [16], and stroke [17], but not in severe TBI,
largely because the underlying mechanisms for TBI-
associated CIRCI remain poorly understood.
Recent clinical evidence suggests that relatively long-
term use of stress-dose of hydrocortisone (HC) (200 mg
per day for 7 days), a natural form of steroid hormone in
humans, significantly reduces mortality in patients with
septic shock and CIRCI without increasing adverse events
[15]. More importantly, stress-dose HC has also been
shown to decrease the incidence of hospital-acquired
pneumonia and the time on mechanical ventilation in
patients with polytrauma and CIRCI. It is particularly
efficient for polytrauma patients with TBI [14]. Recentexperimental data suggest that HC could upregulate metal
homeostasis regulator MT-1/2 [18] and anti-apoptotic fac-
tor PKCε to protect the brain [19]. HC has also been dem-
onstrated to maintain the integrity of endothelial cell tight
junctions and to stabilize the blood–brain barrier (BBB) as
a mode of glucocorticoid action at a molecular level in the
human brain vasculature [20]. However, no data on the
use of stress-dose HC to treat CIRCI in severe TBI are
available to date. Whether it reduces CIRCI and improves
prognosis after severe TBI remains unknown.
Accordingly, we hypothesize that stress-dose of hydro-
cortisone decreases neural apoptosis and restores BBB
function in the hypothalamus, thus boosting the acute
corticosteroid response and reducing post-traumatic
CIRCI and TBI mortality. We tested this hypothesis in a
rat model of experimentally controlled TBI.
Materials and methods
Animal care and experiments were conducted in accord-
ance with the ethical approvals stipulated by the Small
Animal Protection Board of Tianjin Medical University.
Animals
Male Wistar rats weighing 300 to 350 g at the time of sur-
gery were supplied by Experimental Animal Laboratories
of the Academy of Military Medical Sciences (Beijing,
China). Rats were housed individually in a temperature-
controlled (22°C) and humidity-controlled (60%) condi-
tion, and maintained on a standard 12-h light/dark cycle
(7:00 a.m. to 7:00 p.m) with access to food and water ad
libitum. All experimental procedures were performed dur-
ing the light phase between 10:00 a.m. and 2:00 p.m. at
the nadir of the circadian cycle for circulating steroid
in rats.
Rats were grouped by treatments into: naïve, injury
control, HC normal, low-dose methylprednisolone (MP),
and stress-dose HC (Table 1). MP, which is a synthetic
glucorticoid drug and has also been shown to reduce
apoptosis and BBB permeability [21,22], was tested in
this setting as the control. The entire experiment
consisted of two parts. In the first part, rats from each
treatment group were randomly assigned to be evaluated
for corticosteroid response and to determine CIRCI inci-
dence after TBI. In the second part, histological examin-
ation was performed on the hypothalamus to evaluate
brain edema, BBB integrity and permeability, and cellu-
lar apoptosis (Figure 1).
Fluid percussion-induced brain injury
Fluid percussion-induced brain injury (FPI) is an exten-
sively characterized and broadly used preclinical model
of closed head injury [23,24]. Briefly, rats were anesthe-
tized with a single intraperitoneal injection of chloral hy-
drate (3.0 ml/kg) and placed in a stereotaxic frame.
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right parietal bone, 2.0 mm lateral from the sagittal su-
ture and 2.5 mm caudal from the coronal suture with in-
tact dura mater. They were subjected to FPI of 3.2 to 3.5
atmosphere (atm) 24 h after craniotomy as we have pre-
viously described [25].
Neurological assessment
Neurological functions were assessed at baseline before
injury, on post-injury day 1, day 3, day 7, and day 14
using the modified neurological severity score (mNSS)
[26]. Assessments in the neuroscore include motor, sen-
sory, reflex, and balance tests. These scores were used 1)
to ensure the relative uniformity in injury severity; 2) to
compare neurological recovery among rats receiving dif-
ferent treatments. The tests were performed by the sameFigure 1 Study design and experimental procedures. (A) Part I: to eval
responses and incident critical illness-related corticosteroid insufficiency aft
the case of injury controls, was intraperitoneally (i.p.) injected daily from 0 t
was administered to 30 rats randomly assigned from each of the four grou
the remaining rats were injected with HC or MP or saline once a day for 7
permeability, and apoptosis in the hypothalamal cells; 22 rats from each of
groups (injury control, low-dose MP, and stress-dose HC) were sacrificed at
content, to detect Evans blue extravasation and expression of CD31 and cl
nick end labeling-positive cells in the hypothalamus.observer who was blinded to the experimental condi-
tions and treatments.
Glucocorticoid administration
After FPI, rats were on a 7-day regimen of either stress-
dose HC (3 mg/kg/d for 5 days, 1.5 mg/kg on day 6,
and 0.75 mg on day 7) [14] or low-dose MP (1 mg/kg/d
for 5 days, 0.5 mg/kg on day 6, and 0.25 mg on day 7)
[27]. As injury controls, naïve rats were given the same
dose of HC. For drug controls rats underwent the same
surgical procedures and FPI, but received an equal vol-
ume of 0.9% saline (Table 1, Figure 1).
Assessment of corticosteroid response
Electrical stimulation
Thirty rats from each of the four experimental groups
were examined for corticosteroid response by being
subjected to electrical stimulation (ES) on four test days:
the seventh day before injury, and post-injury day 3, 7,
and 14 (Figure 1) as described by Ji et al. [28]. In brief,
ear-clip electrodes were placed on both ears of the ani-
mal while awake, and were connected to an electrical
stimulator (unit J18A1; Quanrikang, Beijing, PR China).
An electric current (1s at 90 mA) was applied to induce
acute stress. On the days of electrical stimulation, blood
was collected pre-ES, and at 30 minutes, 90 minutes,
and 24 h post-ES to measure dynamic changes of serum
corticosterone (CORT), the most abundant circulating
steroid in rats. Blood samples were collected from the
orbital sinus under inhaled light anesthesia (enflurane;
Abbott, Shanghai, PR China) into a dry centrifuge tubeuate the effect of stress-dose hydrocortisone (HC) on corticosteroid
er traumatic brain injury; HC or methylprednisolone (MP), or saline in
o 7 days after fluid percussion injury (FPI). Electrical stimulation (ES)
ps: pre-injury day 7, and post-injury day 3, day 7 and day 14. (B) Part II:
days after FPI to evaluate the extent of brain edema, BBB integrity and
the two groups (naïve and normal HC) and 50 from each of the three
each time point (post-injury day 3, 7 and 14) to measure brain water
audin-5, and to quantify terminal deoxynucleotidyl transferase dUTP
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plasma was collected and stored at −80°C for further
CORT assay [29].Serum corticosterone assay and critical illness-related
corticosteroid insufficiency assessment
Serum levels of CORT were measured using a commercial
ELISA kit (Diagnostic Systems Laboratories, Webster,
TX, USA), according to the manufacturer’s instructions.
Corticosteroid responses of injured rats were assessed by
a CORT increase index (CII), which is the difference be-
tween the post-ES peak value and pre-ES baseline value of
CORT, divided by the pre-ES baseline value of CORT. A
CII value less than 2.5 was classified as acute CIRCI as de-
scribed previously [13].Brain water content
Edema in the hypothalamus was determined by measur-
ing brain water content (BWC) as previously described
[30]. Rats were sacrificed with an overdose of chloral hy-
drate (30 ml/kg, i.p.). The brains were promptly removed,
and a thick (5-mm) coronal slice was made from the brain
(beginning at the bregma). The hypothalamus surrounding
the third ventricular area was removed with a 3-mm punch,
and immediately weighed (wet weight) and then placed in
an incubator at 100°C for 24 h. The samples were weighed
again to determine the dry weight. The BWC was calcu-
lated from:
BWC %ð Þ¼ Wet Weight‐Dry Weightð Þ=Wet Weight½ 
 100%
Permeability of the blood–brain-barrier
BBB permeability of the hypothalamus was assessed by
measuring the extravasation of Evans blue (EB) dye. EB
dye injected intravenously binds instantaneously to albu-
min and other plasma proteins and serves as a marker for
plasma exudation [31]. In brief, EB (2% in PBS, Sigma)
was injected slowly through the jugular vein (4 ml/kg) and
allowed to circulate for 1.5 h. Then, rats were sacrificed
and transcardially perfused with 1 × PBS followed by
0.9% saline. The brain was removed and the hypothal-
amus around the third ventricle was obtained as described
above. The tissue was frozen in −55°C isopentane and
freeze dried. Freeze-dried specimens were homogenized
in formamide (1:20) and incubated at 60°C overnight. The
homogenate was centrifuged at 14,000 rpm for 30 minutes
to collect supernatant. EB content in the supernatant
was determined spectrophotometrically at O.D. 620 nm
(Thermo Scientific, Waltham, MA, USA).Detection of neuronal apoptosis
Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) is a well-defined method for detecting
apoptotic DNA fragmentation in a cell [32]. We used
the In Situ Cell Death Detection Kit, POD (Roche,
Mannheim, Germany) to detect apoptosis in the PVN of
the hypothalamus according to the manufacturer’s in-
structions. Rats were sacrificed at designated time points
with overdose of chloral hydrate (30 ml/kg, i.p., Figure 1).
The brain was removed and fixed in 4% paraformalde-
hyde for 24 h. The tissue was then paraffin embedded
and processed for immunohistological examination. Two
successive brain sections from each rat were stained with
H&E and TUNEL staining, respectively [32]. Briefly, 5-μm
coronal sections from the brain (0.7 to 2.3 mm posterior
to the bregma) were affixed to poly-L-lysine-coated slides
and deparaffinized. The sections were rehydrated and
treated with protease K (20 mg/ml in 10 mM Tris–HCl;
pH 7.5 to 8.0) for 30 minutes at room temperature. They
were then incubated at 37°C with the TUNEL reaction
mixture in a humidified chamber for 3.5 h. The reac-
tion was terminated by washing slides with 0.01 M PBS
(pH 7.4) and then incubated with Converter-POD
(anti-fluorescein antibody conjugated with horseradish
peroxidase) for 2.5 h at 37°C, followed by color develop-
ment at 20°C with 3,3-diaminobenzidine (DAB) substrate.
The sections were counterstained with hematoxylin and
mounted with neutral balsam.
Apoptotic cells in bilateral areas of the paraventricular
nucleus (PVN) in the hypothalamus were counted using
light microscopy at 400× (CH20BIMF200; Olympus,
Tokyo, Japan). They were quantified by the total number
of labeled cells in four sections (40 μm apart).
Immunohistochemistry and fluorescence intensity
quantification
At designated time points, rats were sacrificed with an
overdose of chloral hydrate (30 ml/kg, i.p.) and immedi-
ately perfused through the heart with the phosphate buf-
fer followed by 2% paraformaldehyde, 10 mM sodium
periodate, and 70 mM L-lysine (2% PLP). The brain was
dissected out, post-fixed by immersion in the same fixative
for 1 h, and incubated in a solution of 30% sucrose over-
night. It was embedded in optimum cutting temperature
(OCT) medium (Sakura, Torrance, CA, USA) on dry ice,
and stored at −80°C. Coronal sections of 10 μm at the
hypothalamus level were made on a cryostat at −20°C and
imprinted on poly-L-lysine-coated slides. These sections
were stained for claudin-5 (a tight-junction marker) and
CD31 (an endothelial cell marker).
After air-drying, the sections were fixed with 2% PLP
and rinsed three times in PBS (pH 7.4). They were
blocked in 1% normal donkey serum in PBS with 0.1%
Triton X-100 (PBS/Tween (PBST)) at room temperature
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Figure 2 Survival of rats after traumatic brain injury. The
number of rats treated with stress-dose hydrocortisone (HC) that
died during the 14-day post-injury follow-up period was significantly
lower compared to those from injury control (summarized in
Table 2). The data were from rats that were evaluated for
corticosteroid response. Rats used for histological analyses were not
included (log-rank test, #Chi-square = 4.344, df = 1, P = 0.0371 as
compared to injury control). MP, methylprednisolone.
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claudin-5 antibody diluted at 1:500 (Abcam Cambridge,
MA, USA) or a mouse anti-CD31 antibody diluted 1:500
(Invitrogen Grand Island, NY, USA) in PBST containing
1% normal donkey serum at 4°C overnight following ex-
tensive washing in PBS; the sections were incubated with
an Alexa Fluor 488-conjugated goat anti-rabbit IgG anti-
body at a dilution of 1:1,000 (Invitrogen) and an Alexa
Fluor 568-conjugated goat anti-mouse IgG antibody
(Invitrogen) for 3 h at room temperature. Images of im-
munofluorescence were captured using an Olympus
IX81 microscope (Shinjuku-ku, Tokyo, Japan).
The bilateral area of the PVN in the hypothalamus from
each section and three sections from each rat were ana-
lyzed. Fluorescence intensities, measured using Image J
software (from the National Institutes of Health, Bethesda,
MD, USA), were averaged for each section, and the three
sections were averaged for each rat.
Statistical analyses
Data were analyzed using SPSS (SPSS Inc., Chicago, IL,
USA). Kaplan-Meier survival analysis with the log-rank
significance test was used to measure the mortality rates
among rats with different treatments. Data on mNSS,
CII, apoptotic cell, BWC, EB extravasation and CD31
and claudin-5 expression were analyzed by analysis of
variance (ANOVA) followed by post hoc least significant
difference (LSD) test or the Dunnett T3 test, whereas
acute CIRCI data were analyzed by the Chi-square test.
The Pearson Chi-square test was performed to assess
the strength of the relationship between the incidence of




A total of 694 Wistar rats were studied. Among them,
532 were subjected to severe FPI of 3.2 to 3.5 atm, which
results in severe TBI. The rest were naïve rats and rats
that received HC without surgery and FPI (Table 1). At
an injury level of 3.2 to 3.5 atm, rats lapsed into uncon-
sciousness with apnea, regaining spontaneous breathing
within 140 to 160 s. Consciousness returned in approxi-
mately 280 to 340 s. Severe disturbances in motor func-
tion and balance were observed after injury. The motor
dysfunction recovered gradually within 7 days, whereas
balance improved more slowly.
Stress-dose hydrocortisone reduced traumatic brain
injury-associated mortality
In the first part of the study (Figure 1), 55 rats did not
survive after injury and HC or MP treatment (Table 2
and Figure 2). The mortality rate of rats receiving stress-
dose HC (43.3%) was significantly lower than those ofrats receiving low-dose MP treatment (66.7%) and was
lower than in the injury control (73.3%) (Figure 2).
Stress-dose hydrocortisone improved neurological
outcomes
We compared mortality among rats from the four ex-
perimental groups during a 14-day follow-up period and
found no difference in mNSS 24 h after FPI (Figure 3).
This indicates that the injury was comparable among
rats in all experimental groups. FPI at 3.2 to 3.5 atm
over the cortex of the right hemisphere led to neuro-
logical deficits measured by mNSS (Figure 3). On post-
injury day 1, injured rats presented with high scores on
motor, sensory and beam balance tests, as well as absent
reflexes and abnormal movements. The recovery of
neurological functions began on day 3 after injury and
lasted to post-injury day 14, when rats suffered from re-
sidual neurological deficiencies, presenting with high
scores on sensory and beam balance tests. The mNSS
scores for the stress-dose HC treatment were signifi-
cantly improved on day 7 (mean 6.5 ± SD 1.4; P <0.05)
and day 14 (4.2 ± 1.6; P <0.05) as compared to those for
low-dose MP treatment group and injury control group
Figure 3 Effects of stress-dose hydrocortisone on neurological
outcomes. Injured rats treated with stress-dose hydrocortisone (HC) had
significantly lower mNSS scores at day 7 and day 14 after traumatic brain
injury when compared with the injury control group. Data are presented
as means ± SD. Analysis of variance: F(2,50) = 7.208, P = 0.002 for day7;
post hoc Dunnett T3 test, #P = 0.000 for stress-dose HC treatment versus
injury control, F(2,32) = 7.762, P = 0.002 for day 14; post hoc least
significant difference test, *P = 0.006 for stress-dose HC treatment versus
injury control. Day 1: n = 30 from each group; day 3: n = 23 from injury
control, n = 23 from low-dose methylprednisolone (MP), n = 26 from
stress-dose HC; day 7: n = 16 from injury control, n = 15 from low-dose
MP, n = 22 from stress-dose HC; day 14: n = 8 from injury control,
n = 10 from low-dose MP, n = 17 from stress-dose HC.
Figure 4 Stress-dose hydrocortisone increases corticosteroid
response after traumatic brain injury. Corticosterone increase
index (CII) of rats treated with stress-dose hydrocortisone (HC) was
significantly higher than that of those from the injury control group
or those treated with low-dose methylprednisolone (MP) on day 7
post-injury. Data are expressed as mean ± standard error of the
mean. (#P <0.001 as compared to HC normal treatment; *P = 0.005
as compared to injury control; çP = 0.022 as compared to low-dose
MP). Pre-injury: n = 30 from each group; day 3: n = 30 from HC
normal, n = 23 from injury control, n = 23 from low-dose MP,
n = 26 from stress-dose HC; day 7: n = 30 from HC normal, n = 16
from injury control, n = 15 from low-dose MP, n = 22 from stress-
dose HC; day 14: n = 30 from HC normal, n = 8 from injury control,
n = 10 from low-dose MP, n = 17 from stress-dose HC.
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and 6.4 ± 1.3, respectively on day 14) (Figure 3).
Stress-dose hydrocortisone increased corticosteroid
response and reduced incidence of critical illness-related
corticosteroid insufficiency
TBI can result in acute activation of the HPA-axis and
ultimately induce rapid secretion of glucocorticoids, nor-
epinephrine, and inflammatory cytokines in order to
strengthen a response to traumatic stress. We measured
the concentration of CORT, the most abundant steroid
released to the peripheral blood in injured rats, in response
to ES. We have previously shown that levels of serum
CORT increase rapidly after ES, peaking at 30 minutes, de-
clining gradually and returning to baseline level by 24 h
[13]. In the same study, we also demonstrated that the CII,
the ratio of increased CORT to the baseline, is a reliable
measure to evaluate the activation of the HPA axis. A CII
value less than 2.5 was closely correlated with TBI mortal-
ity, and considered indicative of CIRCI as described previ-
ously [13].
CII, which was comparable among rats in different
groups before injury, began to decrease on day 3,
reached its lowest point on day 7, and returned to a level
slightly below the baseline on day 14. It was significantly
higher on day 7 in injured rats that received stress-dose
HC (median 3.89, IQR 2.29 to 7.28) or low-dose MP
(median 2.65, IQR 1.23 to 3.84) as compared to control
rats (median 2.29, IQR 1.11 to 3.78) (Figure 4).
Furthermore, the incidence of CIRCI in FPI rats
treated with stress-dose HC (27.3%) was significantly
lower than in those treated with saline (68.8%) or low-dose MP (46.6%) on post-injury day 7 (Figure 5). The
reduction of CIRCI was paralleled with a decrease in
TBI mortality (Pearson Chi-Square = 20.972, P <0.001)
(Figures 2 and 5).
Together, these results suggest that (1) TBI resulted in
acute CIRCI with a peak incidence on day 7 after injury;
(2) stress-dose HC did not induce CIRCI in rats without
injury; (3) stress-dose HC reduced the incidence of
CIRCI after TBI, which may be a key factor for reducing
mortality in rats with severe TBI.
Stress-dose hydrocortisone reduced apoptosis in the
paraventricular nucleii of the hypothalamus
TBI-induced corticosteroid response is initiated by sig-
nals from the PVN of the hypothalamus. Previous stud-
ies have shown that FPI causes neural apoptosis in this
region [13]. Reducing the viability of cells in this region
can negatively impact on the activation of the HPA axis.
We therefore examined if the improvements on CII and
CIRCI in rats treated with stress-dose HC is associated
with reduced apoptosis in PVN cells.
H&E staining showed that cells in the PVN of the
hypothalamus became swollen and vacuolated after FPI.
Over time, neurons shrank and became eosinophilic
with pyknosistic nuclei. Three days after FPI, neuronal
Figure 5 Stress-dose hydrocortisone reduces the incidence of
traumatic brain injury-induced critical illness-related
corticosteroid insufficiency (CIRCI). The incidence of CIRCI in rats
treated with stress-dose hydrocortisone (HC) (27.3%) was
significantly lower than in injury control rats (68.8%) and rats
receiving low-dose methylprednisolone (MP) (46.6%) on post-injury
day 7 (Pearson Chi-square = 6.446, df = 1, P = 0.011 as compared to
injury control). However, a difference was not detected between
stress-dose HC-treated rats and control animals on post-injury day 3
or 14. #P = 0.02 as compared to injury control. Day 3: n = 23 from
injury control, n = 23 from low-dose MP, n = 26 from stress-dose
HC; Day 7: n = 16 from injury control, n = 15 from low-dose MP,
n = 22 from stress-dose HC; day 14: n = 8 from injury control, n= 13
from low-dose MP, n = 17 from stress-dose HC.
Figure 6 Stress-dose hydrocortisone (HC) after traumatic brain
injury decreases apoptosis. Data represent the average number of
terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL)-positive cells in the paraventricular nuclei (PVN) area at 3, 7
and 14 days after injury, and are expressed as mean ± standard error
of the mean. The number of TUNEL-positive cells was significantly
higher in all injury groups compared to naïve rats, but they were
significantly lower 7 days after injury in rats treated with stress-dose
HC compared to injury controls. Analysis of variance, F(4,31) = 11.589,
P <0.001 for 7 days; post hoc least significant difference test,
P = 0.041 for the stress-dose methylprednisolone (MP) group versus
injury control. At each time point: n = 3 from each of the two groups
(naïve and HC normal), n = 10 from each of three groups (injury
control, low-dose MP, and stress-dose HC). #P <0.05 as compared to
injury control group; *P <0.05 as compared to naïve group.
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karyolysis were found in many PVN neurons and were
most abundant on day 7 after injury. Figure 6 shows that
TUNEL-positive cells significantly increased in the hypo-
thalamus PVN of injured rats compared to non-injured
rats. The numbers of TUNEL-labeled cells peaked 7 days
after injury, when the incidence of CIRCI was also
highest (Figures 5 and 6). Moreover, the number of
TUNEL-positive cells was significantly reduced in rats
receiving stress-dose HC (median 47.5, IQR 34.75 to
73.25) compared to injury control rats on post-injury
day 7 (median 81.0, IQR 69.25 to 90.25).
Stress-dose hydrocortisone reduced traumatic brain
injury-associated vascular dysfunction
TBI compromises cerebral auto-regulation and breaks
down the BBB, allowing blood cells and plasma infiltrate
into the brain [33]. Several studies have shown that FPI
causes an increase in vascular permeability, primarily in
the ipsilateral hemisphere [30,34,35]. Figure 7C shows
that TBI increased EB extravasation in the hypothalamus
of injured rats as compared with control animals, and
the post-injury administration of stress-dose HC signifi-
cantly reduced this extravasation 3 days after injury. The
same effects were also observed after low-dose MP ad-
ministration, but to a lesser extent. No significantdifferences were observed among groups on either day 7
or 14 after injury. Figure 7D shows that water content in
the hypothalamus increased significantly on post-injury
day 3 and returned to pre-injury level on post-injury day
7. Both stress-dose HC and low-dose MP significantly
reduced the water content 3 days after injury, but at dif-
ferent levels.
Stress-dose hydrocortisone reduced traumatic brain
injury-induced loss of endothelial cell and tight
junction protein
Figure 8A and B are representative immunofluorescence
images of blood vessels labeled with CD31 and claudin-5
in the PVN of the ipsilateral hypothalamus. CD31, a re-
ceptor on endothelial junctions, was used to define the
location of the blood vessel. Consistent with it being
expressed at tight junctions of endothelium, claudin-5 is
localized to the plasma membrane as a continuous strip-
like staining pattern along the vasculature. Figure 8C
shows that brain injury significantly decreased the im-
munoreactivity of CD31 and claudin-5 after injury. They
were lowest on post-injury day 3, when significant BBB
leakage was also detected by EB extravasation. Import-
antly, the immunoreactivity was significantly increased
Figure 7 Stress-dose hydrocortisone results in reduced blood–brain-barrier permeability in the hypothalamus. Representative
photographs of the brains from the stress-dose hydrocortisone (HC) group (A) and injury control group (B) and following Evans Blue (EB) dye injection
on post-injury day 3. Summary data present the EB extravasation (C) and brain water content (D) in the hypothalamus at 3, 7 and 14 days after injury.
The water content of the hypothalamus was significantly decreased in the stress-dose HC-treated rats as compared to injury controls (analysis of
variance (ANOVA), F(4,31) = 5.474, P = 0.002; post hoc least significant difference test (LSD), P = 0.001 for stress-dose HC versus injury control), and
significant reduction in EB extravasation was also observed in the injured rats treated with stress-dose HC at 3 days after traumatic brain injury
(ANOVA, F(4,31) = 9.729, P = 0.000; post hoc LSD, P = 0.002 for stress-dose HC versus injury control). At each time point: n = 3 from each of the two
groups (naïve and HC normal), n = 10 from each of three groups (injury control, low-dose methylprednisolone (MP), and stress-dose HC). *P <0.05 as
compared to naive; #P <0.05 as compared to injury control. Data were expressed as mean ± standard error of the mean.
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when overt improvement of BBB permeability was also
observed. Stress-dose HC appears to protect the levels
of claudin-5 expression, suggesting that the vascular in-
tegrity may have been preserved. Compared with a
moderate increase in CD31 expression, increase in
claudin-5 expression in the hypothalamus was more in-
tensely detected by immunohistochemical staining and
western blot, suggesting the preservation of tight junc-
tions (Figure 8C and D).
Discussion
In the present study, we examined changes in the cor-
ticosteroid response of rats to experimentally controlled
severe FPI to the brain and correlated such changes to
BBB dysfunction and neuronal apoptosis in the PVN of
the hypothalamus. We compared these changes between
rats receiving a 7-day treatment of stress-dose HC and
those receiving low-dose MP. Our findings can be summa-
rized as follows. First, 30 to 70% of injured rats developed
CIRCI, peaking on post-injury day 7. The TBI-associated
CIRCI was closely correlated with increased mortality and
delayed neurological recovery. Second, post-injury treat-
ment of rats with stress-dose HC reduced TBI-associated
mortality and improved the recovery of neurological func-
tions. Moreover, it increased corticosteroid response and
prevented the development of CIRCI, which closely corre-
lates with mortality. Third, stress-dose HC reduced neural
apoptosis, preserved endothelial tight junction, and re-
duced BBB permeability in the PVN of the hypothalamus,starting on post-injury day 3. However these effects of
stress-dose HC have not been observed in rats treated with
low-dose MP.
There is increasing evidence to suggest that the dys-
function of the HPA axis occurs in a variety of critically
ill patients, and is referred to as CIRCI [14,36]. Research
and clinical interest has been increasingly focused on
understanding the role of CIRCI in the pathological
course of severe TBI. A recent retrospective clinical ana-
lysis suggests that CIRCI could develop in up to 50 to
70% of trauma patients with a mortality of 34% despite
pharmacotherapy. To the best of our knowledge, no data
on the spectrum of CIRCI in severe TBI are available to
date. The detection of CIRCI in experimental animals
has been difficult because there are no universally ac-
cepted diagnostic criteria [37]. We have previously de-
scribed a set of criteria that can be used to define CIRCI
in rats subjected to FPI based on an ES test that mimics
acute stress, which activates the HPA axis in the sub-
acute phase of TBI [13]. Using this platform, we found
30 to 70% of TBI rats developed CIRCI, with a peak inci-
dence on post-injury day 7. The TBI-induced CIRCI was
closely correlated with increased mortality and delayed
neurological recovery.
Stress-dose HC, equivalent to the maximal endocrine se-
cretion rate during critical illness, has been recommended
for CIRCI patients with ARDS [2]. It has been reported to
reduce death in these patients without increasing adverse
events [38]. Emerging evidence suggests that this treatment
could also reduce the occurrence of hospital-acquired
Figure 8 (See legend on next page.)
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Figure 8 Stress-dose hydrocortisone reduces the loss of CD31 and claudin-5 in the paraventricular nuclei (PVN) of the hypothalamus
following trauamatic brain injury (TBI). (A) Representative images of blood vessels in ipsilateral hypothalamus, immunostained for endothelial
cell marker CD31, and tight junction protein Claudin-5. Stress-dose hydrocortisone (HC) appears to partially preserve loss of CD31 and claudin-5 caused
by TBI, more pronounced with claudin-5. (B) Region of interest for immunoreactivity analysis was the PVN of the bilateral hypothalamus. Blue square
indicates where the immunofluorescence pictures (A) were taken. (C) Summary data shows immunoreactivity of CD31 and claudin-5 were lowest on
post-injury day 3, when significant BBB leakage was detected by EB extravasation measurement. Importantly, they were significantly increased by the
administration of stress-dose HC, when overt improvement of BBB permeability was also observed. Analysis of variance (ANOVA), F(4,45) = 54.625,
P = 0.000 for CD31 comparison on day 3; post hoc least significant difference (LSD), P = 0.001 for stress-dose HC versus injury control, P = 0.000 for
injury control versus naïve. F(4,45) = 82.263, P = 0.000 for claudin-5 comparison; post hoc Dunnett T3, P = 0.000 for stress-dose HC versus injury control,
P = 0.000 for injury control versus naive. (D) Representative western blot and summary data shows increased claudin-5 expression in the hypothalamus
following administration of stress-dose HC on post-injury day 3. ANOVA, F(4,31) = 5.716, P = 0.001; post hoc LSD, P = 0.001 for stress-dose HC versus
injury control, P = 0.003 for injury control versus naive. At each time point: n = 3 from each of the two groups (naïve and HC normal), n = 10 from
each of three groups (injury control, low-dose methylprednisolone (MP), and stress-dose HC). Data are mean ± standard error of the mean.
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tients with polytrauma and CIRCI [14]. Consistent with
this, we found that post-injury administration of stress-
dose HC increased the corticosteroid response and attenu-
ated CIRCI following severe TBI. The restoration of the
HPA axis function is closely associated with improved
neurological outcomes and a reduced mortality.
Although the mechanism by which it efficiently reduces
CIRCI-associated mortality is not completely known, the
potent anti-inflammatory properties of stress-dose HC
might enhance or accelerate the recovery of corticosteroid
response to severe TBI. After initial injury, an injured
brain is exposed to exaggerated inflammatory response
and a large amount of cytokines activate the HPA axis.
However, recent studies further suggest that excessive se-
cretion of cytokines might cause CIRCI by suppressing
the function of the HPA axis. The serum concentration of
pr-inflammatory mediators, such as IL-6 and TNF-α, were
shown to be markedly increased in CIRCI associated with
septic shock [37] and TBI [39]. TNF-α has been shown to
inhibit adrenocorticotrophic hormone (ACTH)-induced
production of cortisol by suppressing the steroidogenic
expression of P450 enzyme [40]. Stress-dose HC has
been shown to efficiently suppress the production and
activity of pro-inflammatory cytokines during TBI by
inhibiting the nuclear factor (NF)-κB signaling pathway.
This is in a sharp contrast to the high-dose glucocortic-
oid therapy that is reported to increase the risk of death
in TBI [25,41-43].
In the present study, we showed that stress-dose HC
reduced neuronal apoptosis in the PVN of the hypothal-
amus induced by TBI. This observation is consistent with
previous studies by several laboratories, including our
own [13,25,44]. By reducing apoptosis, stress-dose HC
could prevent the disruption of corticotropin releasing
hormone (CRH) transmission in the HPA axis and
reduce CIRCI; both are prevalent in rats with severe TBI.
This anti-apoptotic effect could also explain why stress-
dose HC improves vascular integrity as demonstrated by
reducing the TBI-associated leakage of BBB. A disruptionof BBB will allow the infiltration of circulating cells,
plasma molecules, and fluid into the brain to exacerbate
injury to the brain by FPI [45-48]. Our histological and
immunochemical examinations of injured brain demon-
strate that stress-dose HC increases molecules that are
primarily expressed at the tight junctions of the vascular
endothelium such as claudin-5. Our findings are con-
sistent with previous reports that HC can maintain the
integrity of tight junctions and thus, stabilize the BBB
[20]. The activation of endogenous antioxidant proteins
and inhibition of neuroinflammation restores claudin-5
levels and protects against TBI-induced increase in
BBB permeability [49,50].
In contrast, we found low-dose MP neither reduced
TBI-induced mortality nor improved the recovery of
neurological function, which is the opposite of what we
observed for treatment with stress-dose HC. Low-dose
MP was also less effective in reducing apoptosis and im-
proving BBB permeability in the PVN of the hypothal-
amus compared to stress-dose HC. One can speculate
about the potential causes for this discrapany between the
two gluococorticoids. First, HC has been shown to be four
times more able to activate mineralocorticosteroid recep-
tor (MR), but is four fifth less able to activate the gluco-
corticoid receptor (GR) compared to MP [51]. Recent
studies also suggest that the difference in the rates of acti-
vation of MR and GR may account for this discrepancy
[52]. For example, Chantong et al., show that the balance
between activated MR and GR is critical for neuronal ex-
citability, stress responsiveness and behavioral adaptation.
GR over-activation could modulate the activity of the exci-
tatory and inhibitory neural inputs to the hypothalamic
CRH neurons, and thus, block the stress-induced HPA ac-
tivation in these neurons [53]. However, De Kloet et al.,
suggest limbic MR activation maintains the basal HPA ac-
tivity and the sensitivity or threshold of the central stress
response system [54]. Furthermore, the activation of MR
and GR has pro- and anti- apoptosis effects, depending on
the type of target cells, including those critical for the in-
tegrity of the BBB [55-57].
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the finding 1) can also be observed with female rats and is
gender specific; 2) might be associated with change in par-
tial arterial pressure (Pa)CO2, PaO2 and body temperature,
which are key factors in the evolution of brain injuries, or
the change in cytokine dosing in the brain or in the blood,
which can directly influence hypothalamopituitary func-
tions. Nevertheless, this study suggests that the improve-
ment of BBB integrity and survival of hypothalamic
neurons are two key activities that make stress-dose HC ef-
fective in improving neurological functions and reducing
mortality in rats subjected to severe TBI.
Conclusions
In summary, our findings add to the growing body of
evidence supporting the use of stress-dose HC to im-
prove outcomes of severe TBI. Stress-dose HC reduces
CIRCI and improves neurological recovery, which is as-
sociated with reduction in damage to the tight junctions
of vascular endothelial cells and neuronal apoptosis in
the PVN of the hypothalamus. Therefore, translating this
strategy to a clinical context may have potentially im-
portant therapeutic significance.
Key messages
 The TBI-associated CIRCI is closely correlated with
increased mortality and delayed neurological
recovery. The peak incidence of CIRCI is on post-
injury day 7
 Post-injury treatment with stress-dose HC reduces
TBI-associated mortality and improves the recovery
of neurological function
 Stress-dose HC treatment increases corticosteroid
response and prevents the development of CIRCI,
which closely correlates with reduction in mortality
 Stress-dose HC treatment reduces neural apoptosis,
preserves endothelial tight junctions, and reduces
BBB permeability in the PVN of hypothalamus
 Stress-dose HC can be considered as a potential
treatment for TBI-induced CIRCI
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